TORONTO and RIONEGRO, Colombia , Feb. 8, 2023 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has received a purchase order for CBD Isolate as an API from a large Brazilian pharmaceutical company. The Customer is in the final stages of testing PharmaCielo's API in order to register PharmaCielo as its supplier. The Company anticipates that testing will be complete in Q3 of 2023, with commercial shipments to begin in by Q4 2023.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
